Orbit Discovery Ltd.. (12/3/24). "Press Release: Orbit Discovery and Evergreen Theragnostics Expand Research Collaboration to Advance Targeted Therapeutics Development". Oxford & Springfield, NJ.

	Organisation	Orbit Discovery Ltd.
	Organisation 2	Evergreen Theragnostics Inc.
	Product	RADIOPHARMACEUTICAL (RPT)
	Product 2	drug discovery services
	Person	Butt, Neil (Orbit Discovery 202106– CEO before Iontas + Abzena + Antitope)
	Person 2	Reiner, Thomas (Tom) (Evergreen Theragnostics 202412 CSO)

Orbit Discovery, a leading provider of peptide discovery services, and Evergreen Theragnostics, a radiopharmaceutical company at the forefront of precision medicine, today announced an extension to their research collaboration to find novel targeting peptides for radiopharmaceutical delivery. This collaboration expands upon a previous agreement signed between the companies in April 2023 whereby technology synergies have enabled the identification of high-affinity peptide ligands optimized for precision therapeutic applications1.

The expanded collaboration will leverage Orbit Discovery’s proprietary screening platform to identify and optimize peptide candidates, combined with Evergreen Theragnostics’ expertise in radiopharmaceutical development and clinical translation. The ongoing partnership underscores a shared vision to advance next-generation targeted therapies, with a focus on speed, precision, and efficacy.

“Our collaboration with Evergreen Theragnostics has proven to be a powerful example of how complementary expertise can drive ground-breaking innovation,” said Dr. Neil Butt, CEO of Orbit Discovery. “We are excited to continue building on our achievements and leveraging our proprietary platform to discover peptides with therapeutic potential.”

Dr. Butt added “Evergreen Theragnostics’ radiopharmaceutical expertise provides a strong foundation for transforming these peptides into advanced therapies, particularly in oncology. The partnership exemplifies the commitment of both companies to delivering patient-centric solutions in the rapidly expanding radiopharmaceutical market.”

“We are thrilled to extend our collaboration with Orbit Discovery,” said Dr. Thomas Reiner, CSO of Evergreen Theragnostics. “The Company’s peptide discovery platform has proven invaluable in our mission to develop precision-targeted radiopharmaceuticals. Together, we aim to expedite the journey from discovery to clinical application, creating novel therapies with the potential to improve outcomes for cancer patients.”

Orbit Discovery will be attending the Biotech Showcase in San Francisco, CA, USA, January 13th – 15th 2025 and will be at the partnering event at BIO-Europe Spring in Milan, Italy, March 17th – 19th 2025.

For further information, please visit: https://www.orbitdicovery.com

1. Press release (3rd April, 2023): Orbit Discovery and Evergreen Discovery collaborate to discover peptides for targeting radiopharmaceuticals

ENDS

Notes to Editors

For further information please contact:

Orbit Discovery Ltd
Neil Butt, CEO
Tel: +44(0)1865 749234
Email: [email protected]

Zyme Communications
Lily Jeffery
Tel: +44(0)7891 477 378
Email: [email protected]

About Orbit Discovery www.orbitdiscovery.com

Orbit Discovery (Orbit) is a biologics discovery services company, focussed on peptides and small antibody-like scaffold proteins. The Company’s proprietary platform is a novel bead-based, DNA encoded, discovery technology that utilises microfluidics for high throughput functional or affinity screening. The platform has several benefits over other technologies, such as phage and ribosomal display, with the ability to screen directly on cell surfaces as well as perform cell based functional assays directly on libraries. Orbit’s platform is ideal for finding targeting peptides specifically for nucleic acids or radio-biopharmaceuticals delivery, components of molecular glues and PROTACs, and functional molecules against GPCRs. Orbit is based in Oxford, UK and benefits from the expertise and experience of its founders, Professor Graham Ogg (University of Oxford) and Professor Terry Rabbits (the Institute of Cancer Research).

For more information, please visit www.orbitdiscovery.com
Follow us on LinkedIn: www.linkedin.com/company/orbit-discovery

About Evergreen Theragnostics, Inc.

Evergreen Theragnostics is focused on improving the available options for cancer patients using radiopharmaceuticals. The company is engaged in Contract Development and Manufacturing (CDMO) services as well as drug discovery and commercialization of proprietary products. With a state-of-the-art global GMP facility opened in 2021, Evergreen provides highly reliable manufacturing services for therapeutic and centrally distributed diagnostic radiopharmaceuticals, from early development through commercialization. Evergreen is headquartered in Springfield, NJ, and was founded in 2019 by a team that brings a strong track record in theragnostic radiopharmaceutical manufacturing, research, and clinical development.

For more information, please visit www.evergreentgn.com

Follow us on LinkedIn: https://www.linkedin.com/company/evergreentgn.

Record changed: 2024-12-19